ATE216238T1 - Arzneimittel enthaltend lipidsenkende verbindungen - Google Patents
Arzneimittel enthaltend lipidsenkende verbindungenInfo
- Publication number
- ATE216238T1 ATE216238T1 AT98954483T AT98954483T ATE216238T1 AT E216238 T1 ATE216238 T1 AT E216238T1 AT 98954483 T AT98954483 T AT 98954483T AT 98954483 T AT98954483 T AT 98954483T AT E216238 T1 ATE216238 T1 AT E216238T1
- Authority
- AT
- Austria
- Prior art keywords
- products containing
- medicinal products
- containing lipid
- lowering compounds
- lowering
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97203407 | 1997-11-03 | ||
| PCT/EP1998/006998 WO1999022738A1 (en) | 1997-11-03 | 1998-10-27 | Compositions of lipid lowering agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE216238T1 true ATE216238T1 (de) | 2002-05-15 |
Family
ID=8228898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98954483T ATE216238T1 (de) | 1997-11-03 | 1998-10-27 | Arzneimittel enthaltend lipidsenkende verbindungen |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6342245B1 (de) |
| EP (1) | EP1028730B1 (de) |
| JP (1) | JP2001521899A (de) |
| KR (2) | KR20010023661A (de) |
| CN (1) | CN1278175A (de) |
| AR (1) | AR013739A1 (de) |
| AT (1) | ATE216238T1 (de) |
| AU (1) | AU746890B2 (de) |
| BG (1) | BG104338A (de) |
| BR (1) | BR9814109A (de) |
| CA (1) | CA2307097A1 (de) |
| DE (1) | DE69804994D1 (de) |
| EE (1) | EE200000186A (de) |
| HU (1) | HUP0004139A3 (de) |
| NO (1) | NO20002279D0 (de) |
| NZ (1) | NZ503413A (de) |
| PL (1) | PL340305A1 (de) |
| SK (1) | SK5972000A3 (de) |
| WO (1) | WO1999022738A1 (de) |
| ZA (1) | ZA989997B (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03011784A (es) | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
| US20030059487A1 (en) * | 2001-09-21 | 2003-03-27 | Niazi Sarfaraz K. | Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals |
| US20040220240A1 (en) * | 2001-11-28 | 2004-11-04 | Pellegrini Cara A. | Method of increasing the extent of absorption of tizanidine |
| US6455557B1 (en) * | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
| MXPA06003452A (es) * | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente. |
| DE602004032149D1 (de) * | 2003-09-26 | 2011-05-19 | Alza Corp | Oros-push-stick für die kontrollierte abgabe von wirkstoffen |
| EP2184058B1 (de) | 2003-09-26 | 2012-02-08 | ALZA Corporation | Arzneistoffcoating mit hohem Wirkstoffanteil sowie Methoden zu dessen Herstellung |
| NZ546182A (en) * | 2003-09-26 | 2009-08-28 | Alza Corp | Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen |
| CN101664411A (zh) | 2003-11-14 | 2010-03-10 | 味之素株式会社 | 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂 |
| JP2008504229A (ja) * | 2004-04-09 | 2008-02-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 過剰体重および肥満症患者のための間欠的投薬レジメン |
| WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
| ES2576633T3 (es) * | 2005-08-08 | 2016-07-08 | Abbvie Deutschland Gmbh & Co Kg | Formas de dosificación con una biodisponibilidad mejorada |
| EP1938804A1 (de) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmazeutische Zubereitung enthaltend Neurokinin Antagonist |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| WO2010143199A1 (en) | 2009-06-11 | 2010-12-16 | Suven Nishtaa Pharma Private Limited | Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521186A (en) * | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| RO118715B1 (ro) * | 1994-10-27 | 2003-09-30 | Janssen Pharmaceutica Nv | Inhibitori ai sintezei apolipoproteinei-b |
-
1998
- 1998-10-27 EP EP98954483A patent/EP1028730B1/de not_active Expired - Lifetime
- 1998-10-27 KR KR1020007002314A patent/KR20010023661A/ko not_active Withdrawn
- 1998-10-27 BR BR9814109-0A patent/BR9814109A/pt not_active IP Right Cessation
- 1998-10-27 KR KR1020007002383A patent/KR20010023729A/ko not_active Ceased
- 1998-10-27 CN CN98810808A patent/CN1278175A/zh active Pending
- 1998-10-27 JP JP2000518671A patent/JP2001521899A/ja not_active Withdrawn
- 1998-10-27 PL PL98340305A patent/PL340305A1/xx unknown
- 1998-10-27 EE EEP200000186A patent/EE200000186A/xx unknown
- 1998-10-27 NZ NZ503413A patent/NZ503413A/en unknown
- 1998-10-27 AU AU11576/99A patent/AU746890B2/en not_active Ceased
- 1998-10-27 US US09/530,170 patent/US6342245B1/en not_active Expired - Fee Related
- 1998-10-27 CA CA002307097A patent/CA2307097A1/en not_active Abandoned
- 1998-10-27 HU HU0004139A patent/HUP0004139A3/hu unknown
- 1998-10-27 DE DE69804994T patent/DE69804994D1/de not_active Expired - Lifetime
- 1998-10-27 SK SK597-2000A patent/SK5972000A3/sk unknown
- 1998-10-27 WO PCT/EP1998/006998 patent/WO1999022738A1/en not_active Ceased
- 1998-10-27 AT AT98954483T patent/ATE216238T1/de not_active IP Right Cessation
- 1998-11-02 AR ARP980105502A patent/AR013739A1/es not_active Application Discontinuation
- 1998-11-02 ZA ZA9809997A patent/ZA989997B/xx unknown
-
2000
- 2000-04-14 BG BG104338A patent/BG104338A/xx unknown
- 2000-04-28 NO NO20002279A patent/NO20002279D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1278175A (zh) | 2000-12-27 |
| BG104338A (en) | 2000-12-29 |
| AU1157699A (en) | 1999-05-24 |
| SK5972000A3 (en) | 2000-12-11 |
| AU746890B2 (en) | 2002-05-02 |
| NO20002279L (no) | 2000-04-28 |
| AR013739A1 (es) | 2001-01-10 |
| BR9814109A (pt) | 2000-10-03 |
| JP2001521899A (ja) | 2001-11-13 |
| KR20010023661A (ko) | 2001-03-26 |
| HUP0004139A2 (hu) | 2002-02-28 |
| US6342245B1 (en) | 2002-01-29 |
| PL340305A1 (en) | 2001-01-29 |
| NZ503413A (en) | 2001-06-29 |
| EP1028730A1 (de) | 2000-08-23 |
| HUP0004139A3 (en) | 2002-03-28 |
| KR20010023729A (ko) | 2001-03-26 |
| CA2307097A1 (en) | 1999-05-14 |
| NO20002279D0 (no) | 2000-04-28 |
| WO1999022738A1 (en) | 1999-05-14 |
| DE69804994D1 (de) | 2002-05-23 |
| EE200000186A (et) | 2001-04-16 |
| ZA989997B (en) | 2000-05-02 |
| EP1028730B1 (de) | 2002-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE248594T1 (de) | Irbesartanhaltiges arzneimittel | |
| CY2005007I2 (el) | Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη | |
| DK0812195T3 (da) | Farmaceutisk sammensætning til piperidinoalkanolforbindelser | |
| ATE240732T1 (de) | Ziprasidonhaltige arzneimittel | |
| NO962606L (no) | Farmasöytisk sammensetning | |
| PT858325E (pt) | Formulacao farmaceutica liofilizada estavel | |
| ATE202472T1 (de) | Arzneimittel enthaltend oxaliplatin | |
| FI970995L (fi) | Farmaseuttisia yhdisteitä | |
| ATE216238T1 (de) | Arzneimittel enthaltend lipidsenkende verbindungen | |
| BR9610396A (pt) | Formulação farmacêutica | |
| FI954243A7 (fi) | Farmaseuttiset yhdisteet | |
| BR9610214A (pt) | Compostos farmacéuticos | |
| LV11727A (lv) | Farmaceitiska kompozicija | |
| IT1302969B1 (it) | Confezione per sostanze medicinali | |
| FI973280L (fi) | Farmaseuttinen koostumus | |
| ATE269337T1 (de) | Trizyclische delta3-pyridine als arzneimittel | |
| FI973230A0 (fi) | Uusi farmaseuttinen formulaatio | |
| DE60008237D1 (de) | Lamivudin enthaltende arzneimittel | |
| NO965448D0 (no) | Farmasöytiske forbindelser | |
| DE69811253D1 (de) | Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel | |
| NO964309D0 (no) | Farmasöytisk sammensetning | |
| ATE332709T1 (de) | Stabilisiertes arzneimittel enthaltend cysteinylderivate | |
| GB9511166D0 (en) | Pharmaceutical compounds | |
| GB9502811D0 (en) | Pharmaceutical compounds | |
| GB9517865D0 (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |